Trevena Inc. is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. Their pipeline includes OLINVYK® (oliceridine) injection, which is an FDA-approved opioid agonist designed for the management of acute pain. OLINVYK is notable for its rapid onset of action, with pain relief typically occurring within 1-3 minutes after administration. The drug is characterized by a well-established safety profile, which includes predictable analgesia without active metabolites, thereby reducing concerns related to dose stacking. Trevena emphasizes that OLINVYK is intended as a differentiated alternative to conventional intravenous opioids, particularly for patients who have not responded adequately to other treatments.

In addition to OLINVYK, Trevena is advancing several investigational drug candidates, including TRV045, TRV250, and TRV734, which target various CNS conditions such as diabetic neuropathic pain, acute migraine, and opioid use disorder, respectively. These investigational therapies are based on cutting-edge research, including Nobel Prize-winning science, and are currently in various phases of clinical development. Trevena's commitment to innovation is evident in their focus on creating targeted therapies that address significant unmet medical needs in the realm of CNS disorders, aiming to improve patient outcomes and quality of life.

United States

Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.

Central Nervous System (CNS)

Pathological Conditions

Trevena Inc

Pain

Oliceridine is a full opioid agonist and is relatively selective for the mu-opioid receptor. The
principal therapeutic action of oliceridine is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oliceridine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory, and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.
<a href="http://olinvyk.com/docs/OLINVYK_Final_Label_Ver%20002_Nov2020_1103.pdf">Source</a>

OLINVYK™ (oliceridine)

Migraines

Trevena is developing TRV250 for the acute treatment of migraine. &nbsp;Unlike currently approved migraine therapies, it targets the &nbsp;delta-opioid receptor (delta receptor). Using a novel mechanism of &nbsp;action, TRV250 preferentially engages the signaling pathway responsible &nbsp;for efficacy, with reduced activation of the signaling pathway &nbsp;associated with delta receptor-mediated adverse effects.
The delta receptor is located throughout the brain and plays a role in regulating pain, mood, and anxiety.2 However, the therapeutic potential of this receptor in CNS-mediated &nbsp;diseases has remained largely untapped, due to debilitating adverse &nbsp;effects associated with this receptor target.3 The discovery &nbsp;innovations made by Trevena have yielded TRV250, a compound that, in &nbsp;non-clinical and early clinical studies, appears to reduce the risk of &nbsp;such adverse effects, thus opening the possibility of investigating the &nbsp;therapeutic benefits of a delta receptor agonist in humans.
<a href="https://www.trevena.com/pipeline/trv250">Source</a>

TRV250 (Delta receptor agonist)

Central nervous system illness

Epilepsy

Selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator

TRV045 (S1P receptor)

Opioid use disorder

Through a&nbsp;collaboration with the National Institute on Drug Abuse &nbsp;(NIDA), Trevena is developing TRV734 for use in medication-assisted &nbsp;therapy for the treatment of opioid use disorder. Similar to current &nbsp;standard treatment options, it targets the mu receptor, but with an &nbsp;optimized mechanism of action that preferentially engages the signaling &nbsp;pathway responsible for therapeutic effect, with reduced activation of &nbsp;the signaling pathway responsible for mu receptor-mediated adverse &nbsp;effects. There is nonclinical and clinical evidence to suggest that &nbsp;TRV734 is associated with less constipation.
<a href="https://www.trevena.com/pipeline/trv734">Source</a>

TRV734 (Mu receptor agonist)

Acute respiratory distress syndrome

COVID-19

Infectious disease

TRV027 is a novel AT1 receptor selective agonist that is currently being investigated by multiple institutions as a potential treatment for acute lung injury contributing to ARDS and abnormal blood clotting in COVID-19 patients. It has previously been studied in 691 individuals, has a well-characterized pharmacokinetic profile, and has demonstrated efficacy, potency, and selectivity at the AT1 receptor in nonclinical studies. In previous clinical trials, there was a low dropout rate associated with TRV027, and no significant safety issues were reported. TRV027 is currently being evaluated in the REMAP-CAP COVID-19 ACE2 RAS Modulation Domain, an international, multi-site, randomized, Phase 2 / 3 adaptive clinical trial in hospitalized COVID-19 patients. In April 2021, the Company filed a non-provisional patent application and PCT application with the United States Patent and Trademark Office covering the use of TRV027 to treat ARDS and the prevention or treatment of abnormal clotting in COVID-19 patients.

Trevena Inc

Company Details